PL2034844T3 - Sposób leczenia biegunkowej postaci zespołu jelita drażliwego - Google Patents

Sposób leczenia biegunkowej postaci zespołu jelita drażliwego

Info

Publication number
PL2034844T3
PL2034844T3 PL07761541T PL07761541T PL2034844T3 PL 2034844 T3 PL2034844 T3 PL 2034844T3 PL 07761541 T PL07761541 T PL 07761541T PL 07761541 T PL07761541 T PL 07761541T PL 2034844 T3 PL2034844 T3 PL 2034844T3
Authority
PL
Poland
Prior art keywords
treatment
bowel syndrome
irritable bowel
diarrheal
diarrheal form
Prior art date
Application number
PL07761541T
Other languages
English (en)
Inventor
Barry Quart
David Rosenbaum
Thomas Neenan
Robert Blanks
Original Assignee
Napo Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38648619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2034844(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Napo Pharmaceuticals, Inc. filed Critical Napo Pharmaceuticals, Inc.
Publication of PL2034844T3 publication Critical patent/PL2034844T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL07761541T 2006-05-01 2007-04-30 Sposób leczenia biegunkowej postaci zespołu jelita drażliwego PL2034844T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79707406P 2006-05-01 2006-05-01
US11/510,152 US20070254050A1 (en) 2006-05-01 2006-08-24 Method for treatment of diarrhea-predominant irritable bowel syndrome

Publications (1)

Publication Number Publication Date
PL2034844T3 true PL2034844T3 (pl) 2017-09-29

Family

ID=38648619

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07761541T PL2034844T3 (pl) 2006-05-01 2007-04-30 Sposób leczenia biegunkowej postaci zespołu jelita drażliwego

Country Status (18)

Country Link
US (3) US20070254050A1 (pl)
EP (1) EP2034844B1 (pl)
JP (2) JP5384329B2 (pl)
KR (2) KR101487919B1 (pl)
AR (1) AR060829A1 (pl)
AU (1) AU2007248172B2 (pl)
CA (1) CA2650294C (pl)
DK (1) DK2034844T3 (pl)
ES (1) ES2628290T3 (pl)
MX (2) MX382400B (pl)
NZ (2) NZ595749A (pl)
PE (1) PE20081569A1 (pl)
PL (1) PL2034844T3 (pl)
PT (1) PT2034844T (pl)
SG (1) SG174025A1 (pl)
TR (1) TR201708043T4 (pl)
TW (2) TWI481410B (pl)
WO (1) WO2007130882A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
ES2616012T3 (es) 2006-05-01 2017-06-09 Napo Pharmaceuticals, Inc. Composiciones para tratar o prevenir enfermedad inflamatoria del intestino
SI2241318T1 (sl) 2006-05-01 2013-04-30 Napo Pharmaceuticals, Inc. Postopek za zdravljenje sindroma iritabilnega ÄŤrevesa s predominantno obstipacijo
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
US8436051B2 (en) * 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
EP2719380A3 (en) * 2008-09-16 2014-07-30 University of Maryland, Baltimore SUR1 inhibitors for therapy
JP4565219B2 (ja) * 2008-12-26 2010-10-20 アサヒビール株式会社 ポリフェノール含有顆粒またはポリフェノール含有チュアブル錠剤およびその製造方法
AU2010303577B2 (en) * 2009-10-06 2015-10-22 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
CN102933569A (zh) * 2009-12-17 2013-02-13 新加坡国立大学 表儿茶素衍生物/低聚物的制备方法及其应用
CN107595836A (zh) * 2010-10-31 2018-01-19 纳珀制药公司 用于治疗hiv相关性腹泻的方法和组合物
US9895341B2 (en) 2011-04-01 2018-02-20 Ocean Spray Cranberries, Inc. Inflammation and immunity treatments
US20140057993A1 (en) * 2011-04-27 2014-02-27 Northshore University Healthsystem Prophylaxis and Treatment of Enteropathogenic Bacterial Infection
JP2015514681A (ja) * 2012-04-23 2015-05-21 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 下痢を伴う過敏性腸症候群の処置方法
CN104902911A (zh) 2012-11-21 2015-09-09 Kbs研究有限公司 草药补充剂及其使用方法
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
KR101579688B1 (ko) 2014-07-08 2015-12-24 재단법인 전남생물산업진흥원 좁쌀풀 추출물을 유효성분으로 함유하는 과민성 대장증후군에 의한 내장 통증 억제예방 또는 치료용 약학 조성물
CN104873485B (zh) * 2015-05-08 2019-02-19 中国药科大学 槲皮素治疗与胃肠道应激失调相关疾病的用途
CN107125440A (zh) * 2016-02-29 2017-09-05 湖南晶天科技实业有限公司 一种饲料添加剂肠溶包衣单宁酸及其制备方法以及一种饲料
IT201600122310A1 (it) 2016-12-01 2018-06-01 Sofar Spa Composizione per uso nella terapia di alterazioni dell'intestino
EP3558296B1 (en) 2016-12-23 2023-06-28 Maregade RX, LLC Low dose product and method for treating diarrhea
KR102195776B1 (ko) * 2017-03-06 2020-12-29 아테나 파르마쎄티크 에스에이에스 라세카도트릴을 포함하는 약학 조성물 및 이를 제조하는 방법
JP7328153B2 (ja) 2017-05-31 2023-08-16 ナポ ファーマシューティカルズ インク． 胆汁酸性下痢、小腸切除又は胆嚢除去及び短腸症候群に関連する下痢を治療するための方法及び組成物
US11857510B2 (en) * 2017-05-31 2024-01-02 Napo Pharmaceuticals, Inc. Methods and compositions for treating congenital diarrhea disorder
CN114007623A (zh) * 2019-06-12 2022-02-01 加利福尼亚大学董事会 治疗胆汁酸性腹泻的方法
CN113975412B (zh) * 2021-12-30 2022-04-05 北京赛尔富森生物科技有限公司 一种评价轮状病毒疫苗有效性的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE446940B (sv) 1983-02-16 1986-10-20 Carl Axel Virdalm Medel for bekempande av sjukdomstillstand i matsmeltningsapparaten innehallande skal eller ytterdelar av ber eller frukter
US4698360B1 (en) 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
DE3564370D1 (en) 1985-08-30 1988-09-22 Nestle Sa Dietetic product with depurating and antidiarrheal activity and process for its preparation
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
SI9011933A (sl) 1990-10-15 1998-06-30 TANIN SEVNICA Kemična industrija p.o. Kostanjev taninski ekstrakt, postopek za njegovo pridobivanje in njegova uporaba
US5234922A (en) 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea
FI962667L (fi) 1996-06-27 1997-12-28 Scanwoven Ab Oy Kuitutuote, menetelmä ja laitteisto kuitutuotteen valmistamiseksi
EP2060183A3 (en) 1996-10-16 2009-06-03 Napo Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
US6281240B1 (en) 1997-04-10 2001-08-28 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US20040063695A1 (en) 2002-09-30 2004-04-01 Alan Verkman Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7208183B2 (en) * 2002-10-05 2007-04-24 Bobrowski Paul J Methods and preparations of the latex from the croton species
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
ES2616012T3 (es) 2006-05-01 2017-06-09 Napo Pharmaceuticals, Inc. Composiciones para tratar o prevenir enfermedad inflamatoria del intestino
SI2241318T1 (sl) * 2006-05-01 2013-04-30 Napo Pharmaceuticals, Inc. Postopek za zdravljenje sindroma iritabilnega ÄŤrevesa s predominantno obstipacijo
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
AU2010303577B2 (en) 2009-10-06 2015-10-22 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
CN107595836A (zh) 2010-10-31 2018-01-19 纳珀制药公司 用于治疗hiv相关性腹泻的方法和组合物
EP2928560A4 (en) 2012-12-07 2016-06-01 Salix Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF HIV-ASSOCIATED DIARRHEA

Also Published As

Publication number Publication date
US20070254050A1 (en) 2007-11-01
KR20130063552A (ko) 2013-06-14
CA2650294A1 (en) 2007-11-15
NZ609344A (en) 2014-08-29
US20150050338A1 (en) 2015-02-19
TWI481410B (zh) 2015-04-21
US9980938B2 (en) 2018-05-29
TWI574694B (zh) 2017-03-21
PE20081569A1 (es) 2009-01-14
EP2034844A4 (en) 2010-11-17
PT2034844T (pt) 2017-06-26
JP5384329B2 (ja) 2014-01-08
DK2034844T3 (en) 2017-06-06
EP2034844A2 (en) 2009-03-18
TW201434475A (zh) 2014-09-16
KR20090009291A (ko) 2009-01-22
TW200810772A (en) 2008-03-01
JP5820440B2 (ja) 2015-11-24
CA2650294C (en) 2019-01-22
US20120189720A1 (en) 2012-07-26
JP2009535417A (ja) 2009-10-01
MX382400B (es) 2025-03-13
JP2014012695A (ja) 2014-01-23
AU2007248172A1 (en) 2007-11-15
KR101537361B1 (ko) 2015-07-17
EP2034844B1 (en) 2017-03-22
WO2007130882A2 (en) 2007-11-15
AU2007248172B2 (en) 2013-03-21
AR060829A1 (es) 2008-07-16
SG174025A1 (en) 2011-09-29
MX2008013871A (es) 2009-01-07
ES2628290T3 (es) 2017-08-02
NZ595749A (en) 2013-11-29
US8846113B2 (en) 2014-09-30
WO2007130882A3 (en) 2008-02-07
KR101487919B1 (ko) 2015-02-03
TR201708043T4 (tr) 2018-11-21

Similar Documents

Publication Publication Date Title
PL2034844T3 (pl) Sposób leczenia biegunkowej postaci zespołu jelita drażliwego
PL2252148T3 (pl) Sposoby leczenia zespołu jelita drażliwego
DK1986633T3 (da) Behandling af duchennes muskeldystrofi
EP2083049A4 (en) HARDENABLE POLYORGANOSILOXANE COMPOSITION
PL2241318T3 (pl) Sposób leczenia zespołu jelita drażliwego z dominującymi zaparciami
DK3136030T3 (da) Fremgangsmåde til lyofilisering
BRPI0909180A2 (pt) composição farmacêutica, e, método de tratamento de uma doença autoimune
HRP20150003T1 (xx) Sastavi inhibitora dpp-iv
BRPI0909048A2 (pt) composição farmacêutica, e, método de tratamento de uma doença autoimune
ATE528296T1 (de) Polymorphe form von 4-ä3-(4- cyclopropancarbonylpiperazin-1-carbonyl)-4- fluorbenzylü-2h-phthalazin-1-on
EP2067800A4 (en) POLYORGANOSILOXANE COMPOSITION
PL2190883T3 (pl) Sposób obróbki biomasy
DK2004794T3 (da) Fremgangsmåde til mæskning
BRPI0716881A2 (pt) Composições tópicas
DE602007002929D1 (de) Lichtempfindliche Zusammensetzung
BRPI0716466A2 (pt) Tratamento da calda de açúcar
DK2034830T3 (da) Anti-vla-1-antistof til behandling af slagtilfælde
BRPI0717073A2 (pt) Composição detergente e método
DE602007001706D1 (de) Tonerzusammensetzung und Verfahren
BRPI0718145A2 (pt) Método de micronização
PT2099446E (pt) Método de tratamento de doença inflamatória intestinal
BRPI0715728A8 (pt) tratamento de distúrbios cartilaginosos
LU93092I2 (de) Alemtuzumab
EP2046368A4 (en) ANTI-COCAINE COMPOSITIONS AND TREATMENT
EP2132251A4 (en) COMPOSITION AND METHOD